ELOXX PHARMACEUTICALS, INC. (ELOX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -11.88M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 6.15M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-11.88M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-9.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-6.44M | $0.00 | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-2.47M | $6.36M | (m) | (m) | (m) | -38.81% |
| 2023-12-31 | $-17.29M | $0.00 | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-19.29M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-22.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-28.95M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-34.42M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-40.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-43.12M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-68.56M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-66.02M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-60.19M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-56.24M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-28.10M | (m) | (m) | $13.90M | (m) | (m) |
| 2020-12-31 | $-33.45M | (m) | (m) | $14.59M | (m) | (m) |
| 2020-09-30 | $-39.14M | (m) | (m) | $16.99M | (m) | (m) |
| 2020-06-30 | $-45.62M | (m) | (m) | $20.56M | (m) | (m) |
| 2020-03-31 | $-52.34M | (m) | (m) | $24.37M | (m) | (m) |
| 2019-12-31 | $-50.55M | (m) | (m) | $25.84M | (m) | (m) |
| 2019-09-30 | $-53.18M | (m) | (m) | $26.69M | (m) | (m) |
| 2019-06-30 | $-51.76M | (m) | (m) | $25.30M | (m) | (m) |
| 2019-03-31 | $-50.99M | (m) | (m) | $22.11M | (m) | (m) |
| 2018-12-31 | $-47.56M | (m) | (m) | $20.49M | (m) | (m) |
| 2018-09-30 | $-44.03M | (m) | (m) | $22.13M | (m) | (m) |
| 2018-06-30 | $-36.67M | (m) | (m) | $19.99M | (m) | (m) |
| 2018-03-31 | $-26.31M | (m) | (m) | $18.06M | (m) | (m) |
| 2017-12-31 | $-20.39M | (m) | (m) | $16.40M | (m) | (m) |
| 2017-09-30 | $-627.45K | (m) | (m) | $135.64K | (m) | (m) |
| 2017-06-30 | $-4.59M | (m) | (m) | $733.66K | (m) | (m) |
| 2017-03-31 | $-5.46M | (m) | (m) | $1.02M | (m) | (m) |
| 2016-12-31 | $-10.00M | (m) | (m) | $1.47M | (m) | (m) |
| 2016-09-30 | $-12.25M | (m) | (m) | $1.86M | (m) | (m) |
| 2016-06-30 | $-11.19M | (m) | (m) | $2.18M | (m) | (m) |
| 2016-03-31 | $-10.72M | (m) | (m) | $2.61M | (m) | (m) |
| 2015-12-31 | $-7.05M | (m) | (m) | $2.27M | (m) | (m) |
| 2015-09-30 | $-14.04M | (m) | (m) | $3.05M | (m) | (m) |
| 2015-06-30 | $-18.08M | (m) | (m) | $4.57M | (m) | (m) |
| 2015-03-31 | $-20.83M | (m) | (m) | $4.56M | (m) | (m) |
| 2014-12-31 | $-21.74M | (m) | (m) | $5.29M | (m) | (m) |
| 2014-09-30 | $-12.58M | (m) | (m) | $4.65M | (m) | (m) |
| 2014-06-30 | $-9.15M | $182.23K | (m) | $3.34M | (m) | -5019.95% |
| 2014-03-31 | $-6.53M | (m) | (m) | $2.74M | (m) | (m) |
| 2013-12-31 | $-5.45M | (m) | (m) | $2.36M | (m) | (m) |
| 2013-09-30 | $-5.16M | (m) | (m) | $2.30M | (m) | (m) |
| 2013-06-30 | $-4.65M | (m) | (m) | $2.09M | (m) | (m) |
| 2013-03-31 | $-4.84M | (m) | (m) | $2.24M | (m) | (m) |
| 2012-12-31 | $-4.90M | $0.00 | (m) | $2.29M | (m) | (m) |
| 2012-09-30 | $-5.06M | (m) | (m) | $2.45M | (m) | (m) |
| 2012-06-30 | $-5.09M | $200.00K | (m) | $2.57M | (m) | -2545.20% |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $-6.33M | (m) | (m) | $3.72M | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $-4.85M | $140.00K | (m) | $2.64M | (m) | -3461.80% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |